obesity drug news today glp-1 2025 Market Size to Hit USD 66.57 Billion by 2035 Study finds 40% of GLP-1

Governments and health organizations are prioritizing these conditions due to their rising prevalence and associated healthcare costs

10,11 California's spending on the three drugs approved for the weight loss indication increased fourfold from early 2024 to mid 2025, as outlined in Figure 2

Some data suggests that higher doses of tirzepatide may be associated with a higher risk of gastrointestinal issues compared to semaglutide

Newer inhibitors should include hydrogen-bond donor or positively ionizable groups that can interact with the Glu205/206 pair in the N-terminal recognition region, as well as hydrophobic components to engage with the S 1 pocket

The MFPs for the 15 selected drugs will be determined over the next several months pursuant to the regulatory process established by CMS

(2025, August 14)